1. Home
  2. BDTX vs ANGI Comparison

BDTX vs ANGI Comparison

Compare BDTX & ANGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.10

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$4.72

Market Cap

198.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDTX
ANGI
Founded
2014
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
171.9M
198.7M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
BDTX
ANGI
Price
$2.10
$4.72
Analyst Decision
Strong Buy
Buy
Analyst Count
7
7
Target Price
$9.67
$17.00
AVG Volume (30 Days)
506.7K
755.1K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
130.71
1242.86
EPS
N/A
N/A
Revenue
N/A
$736,386,000.00
Revenue This Year
N/A
$3.25
Revenue Next Year
N/A
$3.76
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.60
52 Week Low
$1.60
$4.26
52 Week High
$4.94
$18.38

Technical Indicators

Market Signals
Indicator
BDTX
ANGI
Relative Strength Index (RSI) 52.12 44.58
Support Level $1.98 $4.55
Resistance Level $2.28 $6.52
Average True Range (ATR) 0.10 0.30
MACD -0.02 0.04
Stochastic Oscillator 26.67 24.34

Price Performance

Historical Comparison
BDTX
ANGI

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

Share on Social Networks: